Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis.
about
Nitric oxide and peroxynitrite in health and diseaseNO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialThe impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular diseaseClinical Relevance of Biomarkers of Oxidative StressPharmacology and Clinical Drug Candidates in Redox MedicineRNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclaseReactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical IndicationsOxidative stress associated with middle aging leads to sympathetic hyperactivity and downregulation of soluble guanylyl cyclase in corpus cavernosumFluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cellsFunctional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus.Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.Hypoxia induces downregulation of soluble guanylyl cyclase β1 by miR-34c-5pTargeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vesselsSoluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.NOX1, 2, 4, 5: counting out oxidative stress.Transcriptional and post-transcriptional regulation of cGMP-dependent protein kinase (PKG-I): pathophysiological significanceEffect of oral organic nitrates on expression and activity of vascular soluble guanylyl cyclaseRiociguat for the treatment of pulmonary hypertension.Soluble guanylate cyclase: a potential therapeutic target for heart failure.Novel vasodilators in heart failure.Role of sGC-dependent NO signalling and myocardial infarction risk.Activation of soluble guanylyl cyclase prevents foam cell formation and atherosclerosis.Vasorelaxant and antiaggregatory actions of the nitroxyl donor isopropylamine NONOate are maintained in hypercholesterolemia.Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation.Characterization of the human alpha1 beta1 soluble guanylyl cyclase promoter: key role for NF-kappaB(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor.Effects of the JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) on soluble guanylyl cyclase alpha1 gene regulation and cGMP synthesis.Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.Heparin responses in vascular smooth muscle cells involve cGMP-dependent protein kinase (PKG)Heat shock protein 90 regulates stabilization rather than activation of soluble guanylate cyclase.Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells.Tirofiban increases soluble guanylate cyclase in rat vascular walls: pharmacological and pathophysiological consequences.Chemerin reduces vascular nitric oxide/cGMP signalling in rat aorta: a link to vascular dysfunction in obesity?Widespread Coronary Dysfunction in the Absence of HDL Receptor SR-B1 in an Ischemic Cardiomyopathy Mouse Model.Chronic limb-threatening ischemia could benefit from growth hormone therapy for wound healing and limb salvage.Hypertension alters phosphorylation of VASP in brain endothelial cells.Stimulators of the soluble guanylyl cyclase: promising functional insights from rare coding atherosclerosis-related GUCY1A3 variants.
P2860
Q24645400-D4D2C94B-5EAC-4E79-8F77-4BA87F9D4DECQ24656131-A470C9D9-E27F-4402-87F1-9BD602DA8327Q26748869-9165B79F-235D-4AC4-AD83-7ACCBDCCC965Q26785512-C8C64894-DADB-407A-B044-24D5C47AF023Q26785525-9AF7EFDE-4096-4F34-A590-7BB51E666611Q27001569-D9D5C381-B501-4B56-A46B-8EDA0B93E48FQ27024762-6D22FE9A-F0E8-4F73-B339-0D022A4B5FD1Q28247831-EB0AFA57-CBE9-4938-9F34-AF63EBB79F7EQ28741339-AE502A38-BB5D-4843-B917-F6500BFDFDDFQ30252419-174E59C7-74D1-41CB-81B5-6C6B90741C05Q30315850-F957B38D-5811-4572-971D-9F822920FAC7Q33818129-48918D28-BE47-4362-8800-D6B4BA4AFA65Q35009484-84B9A160-32E9-4063-9F4B-901FA2533028Q35010064-4952DC42-297D-46AE-9D52-B9149F426090Q35375986-B73825A5-C6D7-4226-BB0C-FFC8878750F1Q36529020-B3392935-C1F4-4F43-B412-2DDFE019D8C3Q36938470-CCAC970D-CCBB-4E25-AED6-AE6045FE0098Q37851516-E1758F6B-E1C1-4E8D-8CA2-8740E53E9115Q38012596-DAE5C0CD-C9B3-43C7-BBB1-F0966C7F2438Q38072635-EE14D12B-A22E-4C37-9E9B-8D6262DFC527Q38367012-38430B32-F6D3-411B-9567-0B85CAC6604BQ39050535-2284925D-F0F3-4F84-8D64-0A29A80589ECQ39722744-C73FD064-69DB-43B5-9FE8-DCB14DB8AFAFQ39847509-27C4F417-D080-4887-981F-C0A644DD2AAFQ40088433-3C65BD05-2B58-4E8A-87D0-E41484C47A83Q40423735-B95579CB-D217-4B98-8BD5-A5E71F6168D0Q41329824-9D9EC9CF-9F60-4B3F-958D-4EB2E9E6A332Q41767067-69CE5076-DE69-4C1C-B667-F806A41A7A90Q42030989-6232C4A5-D79C-41E5-AA54-908BDE5A528FQ43159940-C6D829FF-AD7D-48C5-8306-71F0D4931F14Q46173433-C46C74EA-D42E-4EDC-BCEF-D89FC971D4E1Q46935958-F871FBE1-980D-4505-9DB5-73EBBADD44E2Q47159582-451B4102-D121-4B83-AE17-BE2589711DCBQ48358527-BC94C5C1-6D03-49A3-B124-767084E87F46Q48738058-F9DD571B-F8ED-45FE-AEEB-603F0F0F3EFAQ51682930-DEB58073-B4E7-44F1-BCBE-FE912FFCF937
P2860
Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Reduced cGMP signaling associa ...... in late-stage atherosclerosis.
@en
Reduced cGMP signaling associa ...... in late-stage atherosclerosis.
@nl
type
label
Reduced cGMP signaling associa ...... in late-stage atherosclerosis.
@en
Reduced cGMP signaling associa ...... in late-stage atherosclerosis.
@nl
prefLabel
Reduced cGMP signaling associa ...... in late-stage atherosclerosis.
@en
Reduced cGMP signaling associa ...... in late-stage atherosclerosis.
@nl
P2093
P2860
P356
P1476
Reduced cGMP signaling associa ...... in late-stage atherosclerosis.
@en
P2093
Alain Rupin
Arun Kumar H S
Delphine Behr-Roussel
Harald H H W Schmidt
José Rodrigo
L Otto Uttenthal
Tony J Verbeuren
Ulrike Zabel
Volker O Melichar
P2860
P304
16671-16676
P356
10.1073/PNAS.0405509101
P407
P577
2004-11-16T00:00:00Z